Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cerilliant
Federal Trade Commission
AstraZeneca
UBS
Cipla
Healthtrust
Covington
Express Scripts
Johnson and Johnson

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020998

« Back to Dashboard

NDA 020998 describes CELEBREX, which is a drug marketed by Gd Searle and is included in one NDA. It is available from twenty-six suppliers. Additional details are available on the CELEBREX profile page.

The generic ingredient in CELEBREX is celecoxib. There are twenty-six drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the celecoxib profile page.
Summary for 020998
Tradename:CELEBREX
Applicant:Gd Searle
Ingredient:celecoxib
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020998
Medical Subject Heading (MeSH) Categories for 020998
Suppliers and Packaging for NDA: 020998
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CELEBREX celecoxib CAPSULE;ORAL 020998 NDA G.D. Searle LLC Division of Pfizer Inc 0025-1515 0025-1515-01 60 CAPSULE in 1 BOTTLE (0025-1515-01)
CELEBREX celecoxib CAPSULE;ORAL 020998 NDA G.D. Searle LLC Division of Pfizer Inc 0025-1520 0025-1520-31 100 CAPSULE in 1 BOTTLE (0025-1520-31)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength100MG
Approval Date:Dec 31, 1998TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength200MG
Approval Date:Dec 31, 1998TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength400MG
Approval Date:Aug 29, 2002TE:ABRLD:Yes

Expired US Patents for NDA 020998

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-001 Dec 31, 1998 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-002 Dec 31, 1998 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-004 Dec 15, 2006 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-001 Dec 31, 1998 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-003 Aug 29, 2002 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-003 Aug 29, 2002 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-002 Dec 31, 1998 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-003 Aug 29, 2002 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-003 Aug 29, 2002 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-004 Dec 15, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Merck
Citi
Federal Trade Commission
Johnson and Johnson
Cantor Fitzgerald
Novartis
Teva
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot